Novavax Expands Coronavirus Vaccine Capacity To More Than 2B Doses In 2021

Novavax Expands Coronavirus Vaccine Capacity To More Than 2B Doses In 2021

The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with German partner BioNTech.

There are now nine vaccine candidates in late-stage human trials around the world, although some have hit recent obstacles - pharma giant AstraZeneca and Oxford University momentarily paused clinical trials last week after a volunteer developed an unexplained illness.

Coronavirus vaccines being developed in China may be ready for use by the general public as early as November, an official with the Chinese Center for Disease Control and Prevention (CDC) said. In June, China's military approved a vaccine for use within its ranks developed by its research unit and a biotech firm. DSMB, India, has also recommended continuing the study and enrolment of the remaining participants in the clinical trial as per protocol subject to certain conditions.

"You're vaccinating people and you don't know if it's going to protect them", Durbin told Reuters, adding recipients of the experimental vaccines could eschew other protective measures.

About one in seven volunteers who received a groundbreaking Russian coronavirus vaccine have complained of side effects such as muscle pain, weakness, and fever, according to the country's Minister for Health Mikhail Murashko.

Johnson & Johnson was one of nine companies to commit last week to upholding scientific standards in the race for a COVID-19 vaccine amid rising concerns that safety and efficacy standards might slip in the rush to halt the pandemic.

Sputnik V is the world's first coronavirus vaccine and was announced by President Vladimir Putin on August 11.

South Korea will buy 20 million doses of vaccine from the COVAX scheme, enough for 10 million people, and 40 million doses from private drug-makers, health authorities said in a statement.

In the United States, regulators are more hesitant to resume the trial, with the government-funded National Institutes of Health having now launched an investigation of its own, Kaiser Health News reported Monday. The person declined to name the countries engaged in talks.

"That narrative, ironically, may become more convincing when Trump's America First approach denies many countries opportunities to access the US -made vaccines".

Related Articles